Fig. 5
CD133 CAR-T and PD-1 s cells have better antitumour effects than CD133 CAR-T cells in vivo after intravenous injection. A Schematic diagram of CAR-T cell treatment and tumour detection. NCG mice with Hep3B xenograft tumours were intravenous injected with two doses of 5 million Mock T cells, CD133 CAR-T cells or CD133 CAR-T and PD-1 s cells once Hep3B xenograft tumours reached 50–150 mm3, as revealed by bioluminescence imaging. B The tumours of Mock T cell-, CD133 CAR-T cell- and CD133 CAR-T and PD-1 s cell-treated groups were monitored weekly by bioluminescence imaging. C Growth curves of Mock T cell-, CD133 CAR-T cell- and CD133 CAR-T and PD-1 s cell-treated groups in Fig. 5B. D The tumour volumes of the Mock T cell-, CD133 CAR-T cell- and CD133 CAR-T and PD-1 s cell-treated groups were measured by bioluminescence imaging. Mean ± SD, n = 5, two-tailed unpaired Student’s t test, *P < 0.05, **P < 0.01, ***P < 0.001, ns, not significant. E Kaplan–Meier survival curves of Mock T, CD133 CAR-T and CD133 CAR-T and PD-1 s cell-treated groups. **P < 0.01 (log-rank test); ns, not significant. F Representative images of HE, CD133 and CD3 staining of the Mock T, CD133 CAR-T and CD133 CAR-T and PD-1 s cell-treated groups. G Percentage of CD3 expression in tumours in all the mice in Fig. 5F belonging to the Mock T, CD133 CAR-T and CD133 CAR-T and PD-1 s cell-treated groups